CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Sep 7, 2004
Grant Date -
Aug 1, 2002
app pub date -
Sep 20, 2001
filing date -
Sep 22, 2000
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
The invention relates to a method of stimulating antibody-dependent cellular cytotoxicity to enhance the elimination of IgE-bearing B-cells comprising administering to a mammal an anti-IgE antibody, which binds to membrane bound IgE, but does not induce histamine release and administering an ISO to the mammal. The ISO may be a CpG containing oligonucleotide, or a modified CpG-containing oligonucleotide with an electron-withdrawing group at least at position C-5 of the cytosine in the CpG sequence. In addition, the method may include the administration of an allergen to improve desensitization therapy.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully